News

Charcot-Marie-Tooth disease (CMT) is the most common inheritable peripheral neuropathy, affecting millions of people worldwide. Despite its prevalence, many people are unfamiliar with CMT and its impact. That’s why CMTA created a new video to explain what CMT is and raise ...

What is the Nervosave Survey? CMTA-STAR Alliance Partner Nervosave Therapeutics, a France-based biotech company, is seeking participants for an online survey to understand patient perspectives on a new genetic therapy under development for CMT1A. According to the company, the therapy offers ...

NMD Pharma A/S, a CMTA-STAR Alliance Partner, recently announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NMD670, the investigational drug the company is studying in its ongoing Phase II SYNAPSE-CMT clinical trial. ...

The Simply CMT Podcast is presented by the Charcot-Marie-Tooth Association. This monthly podcast highlights the CMT community and the work of CMTA. Simply CMT. Empowering Patients, Accelerating Research. Simplified. Interested in being a guest? Email marketing@cmtausa.org View Archived CMT 4 Me Podcast ...

CMTA-STAR Alliance Partner NMD Pharma A/S has announced the publication of foundational findings in the Annals of Clinical and Translational Neurology. The study highlights neuromuscular junction (NMJ) dysfunction as a characteristic in Charcot-Marie-Tooth disease (CMT) types 1 and 2, identifying ...